Company Performance Metrics
- Nigel MacClancy: CEO
Piton Therapeutics is pioneering the development of life-changing therapeutics for chronic conditions with limited therapeutic options. It employs a proprietary platform to discern the gut microbiome’s role in the cause and progression of disease. Therapeutics are developed to precisely target pathogenic pathways in the gut lumen. AI capabilities
efficiently identify drug candidates with desired characteristics which are validated in the company’s lab. Products consist of small-molecule drugs. Piton does NOT develop live bacterial therapeutics (LBTs) or seek to modify the composition of microbiota in the gut.